Skip to main content

Table 2 Drug-related adverse events of all grades that occurred in ≥ 5% of patients*

From: Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients

Event

No. of Patients (%)

 

APV 600 mg/RTV 100 mg BID (N = 158)

APV 1200 mg BID (N = 53)

Gastrointestinal

  

   Nausea

31 (20)

10 (19)

   Diarrhea

27 (17)

10 (19)

   Vomiting

10 (6)

5 (9)

Non-site specific

  

   Fatigue

11 (7)

4 (8)

Neurology

  

   Headache

9 (6)

2 (4)

   Paresthesia, oral/perioral

3 (2)

4 (8)

Endocrine and metabolic

  

   Hypertriglyceridemia

11 (7)

0

Skin

  

   Rashes

8 (5)

3 (6)

  1. *Adverse events were classified as drug-related based on the investigators' assessment of causality.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us